Spyre Therapeutics, Inc. (SYRE) Stock: Price, Forecast & Analyst Target
Spyre Therapeutics, Inc. (SYRE) — MoonshotScore 26/100 (Weak band), calculated Oct 26, 2026. Price $92.91 (+2.86%), as of the Oct 26, 2026 trading session; market cap $8.53B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 7.45× (market value Oct 26, 2026; cash Jun 30, 2026) · expected results Nov 3, 2026
Spyre Therapeutics, Inc. · SYRE · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Spyre Therapeutics is developing antibody treatments and paired-antibody regimens for inflammatory bowel disease rather than selling an established drug franchise. Its case rests on whether those programs can produce convincing development evidence before rising research activity consumes too much of the company’s financial cushion.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Spyre Therapeutics (SYRE)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but bottom-tier quality and weak growth. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Sound; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $90M (Q4 FY2025, quarter ended Dec 31, 2025)
- EPS beat 5 of 8
- Altman Z 68.82 · Piotroski F 2
Holding back: weak fundamentals
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 25 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak |
The score was 26 in the stored Oct 24, 2026 snapshot and remains 26 in the current publication computed Oct 26, 2026 (0); the largest pillar moves were Growth Durability -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $92.91 |
| Change on the day | +2.86% |
| 52-week range | $21.14–$110.18 |
| Market capitalisation | $8.53B |
| Shares traded on the day | 637.2K |
| Beta (volatility vs the S&P 500) | 3.11 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Spyre Therapeutics (SYRE): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 12, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 26, 2026, except a card that shows its own read date.
Watch the SYRE film — every key number, told as a short cinematic story
~2 min · open the film
What is Spyre Therapeutics (SYRE), and what does it report?
Short answer · as of
Spyre’s portfolio targets inflammatory bowel disease through antibodies directed at an integrin, a tumor necrosis factor-like ligand, and an interleukin pathway, alongside regimens that pair those mechanisms.
Research dated 2026-09-13.
Spyre’s portfolio targets inflammatory bowel disease through antibodies directed at an integrin, a tumor necrosis factor-like ligand, and an interleukin pathway, alongside regimens that pair those mechanisms. The company’s reported economics therefore measure the cost of advancing experimental programs, not demand for marketed therapies.
An isolated revenue entry appears in the quarterly record, but the annual history does not establish recurring product sales. Research spending, operating losses, and cash consumption are the more informative measures of current activity.
What do the latest results show for Spyre Therapeutics (SYRE)?
Short answer · as of
The most recent reported quarter, Q4 FY2025, carried revenue of $90M.
Research dated 2026-09-13.
The latest period showed a narrower operating loss and a much smaller net loss even as research and administrative spending rose. Reported loss per share also came in better than the prevailing estimate, although operating cash use reached the highest level in the displayed series.
The expense mix points to expanding pipeline work as Spyre’s dominant economic activity. The statements support that observation, but they do not attribute the improvement in accounting losses or the heavier cash use to a particular program.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $0.00 Jun 30, 2026
- Latest quarter · R&D
- $65.50M Jun 30, 2026
- Latest quarter · SG&A
- $16.14M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$41.64M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $0.00 | $65.50M | $16.14M | −$41.64M |
| Mar 31, 2026 | $0.00 | $60.41M | $15.23M | −$45.64M |
| Dec 31, 2025 | $90.49M | $44.64M | $12.53M | −$57.17M |
| Sep 30, 2025 | $0.00 | $45.25M | $11.64M | −$56.89M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · EPS vs estimate
- Above estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | Not available | Not available | −$0.3600 | −$0.7589 |
| May 5, 2026 | Not available | Not available | −$0.7400 | −$0.6600 |
| Feb 19, 2026 | $90.49M | Provider row rejected | −$0.7000 | −$0.6600 |
| Nov 4, 2025 | Not available | $2.00M | −$0.1500 | −$0.7608 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 1 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2025 | $90M | -$63M | -$0.70 (diluted) |
What are the financial strengths and risks for Spyre Therapeutics (SYRE)?
Short answer
Cash and short-term investments were $1.15B at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$69.88M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Spyre carries no reported debt and holds a large pool of cash and short-term investments. At the stated annualized cash-use rate, that liquidity implies an extended development runway, while the sharp increase in the cash balance adds near-term financing flexibility.
The counterweight is a rising rate of operating cash consumption and continued dependence on experimental assets. A clinical setback, development delay, or sustained increase in research spending could erode that runway without a marketed franchise to replenish it; moreover, cash represents only part of the company’s market value.
Data-derived red flags
- Negative return on equity (-24.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$69.88M Jun 30, 2026
- Previous quarter · operating cash flow
- −$57.37M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$69.88M | Not available |
| Mar 31, 2026 | −$57.37M | Not available |
| Dec 31, 2025 | −$44.58M | Not available |
| Sep 30, 2025 | −$37.12M | Not available |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Spyre Therapeutics (SYRE)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026. The number it tests is the $-2.72 EPS analysts carry for it.
Research dated 2026-09-13.
Research spending and operating cash use should be watched together: outlays on development have climbed, and cash consumption has accelerated across the recent periods. The scheduled earnings release can clarify whether that divergence continues and whether accounting losses remain volatile relative to cash burn.
Program updates for the integrin, ligand, interleukin, and paired-antibody candidates matter more than near-term sales comparisons. Analyst estimates place meaningful revenue further out, reinforcing that development progress and the durability of the cash runway are the relevant near-term observations.
What the records here don't tell us
- The newest quarter held here (Q4 FY2025) was filed Feb 19, 2026 — 8 months ago.
Checked against the records this page reads, on the dates shown above.
How does Spyre Therapeutics compare with its peers?
Short answer
Spyre Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Compared with commercial biotechnology companies, Spyre offers little insight through conventional sales or margin analysis because its value is attached to an experimental inflammatory bowel disease portfolio. The distinctive feature within development-stage biotechnology is the attempt to combine separately targeted antibodies into paired regimens, making evidence for both the individual mechanisms and their combined use especially consequential.
Its debt-free liquidity gives the portfolio time to develop, but the market value already exceeds the cash position by a wide margin. That makes the company less a balance-sheet proxy than a judgment on whether its concentrated disease strategy can create valuable therapies.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1279.14 Oct 26, 2026 | $1.20T | 98 5-pillar Oct 26, 2026 | |
| $313.66 Oct 26, 2026 | $9.26B | 98 5-pillar Oct 26, 2026 | |
| $308.30 Oct 26, 2026 | $6.05B | 96 5-pillar Oct 26, 2026 | |
| $72.69 Oct 26, 2026 | $11.4B | 93 5-pillar Oct 26, 2026 | |
| $61.61 Oct 26, 2026 | $125B | 92 5-pillar Oct 26, 2026 | |
| $32.45 Oct 26, 2026 | $9.11B | 91 5-pillar Oct 26, 2026 | |
| $87.13 Oct 26, 2026 | $9.33B | 86 5-pillar Oct 26, 2026 | |
| $286.79 Oct 26, 2026 | $505B | 80 5-pillar Oct 26, 2026 | |
| $140.32 Oct 26, 2026 | $9.08B | 75 5-pillar Oct 26, 2026 | |
| $143.35 Oct 26, 2026 | $5.77B | 68 5-pillar Oct 26, 2026 | |
| $54.79 Oct 26, 2026 | $8.29B | 67 5-pillar Oct 26, 2026 | |
| $44.44 Oct 26, 2026 | $7.46B | 66 5-pillar Oct 26, 2026 | |
| Spyre Therapeutics (SYRE) — this page | $92.91 | $8.53B | 26 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $107.00 – $130.00
- Consensus target
- $119.89
- Median target
- $120.00
- Revenue estimate
- $88,600
- EPS estimate
- $-2.72
Consensus record · Captured .
Measured against a quoted price of $92.91 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 100
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 64
- Other transactions
- 36
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 276 Period end Jun 30, 2026
- Previous quarter · holders
- 201 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 13,026,187 |
| Blackrock, INC. | 6,506,605 |
| Perceptive Advisors LLC | 4,319,496 |
| Rtw Investments, LP | 4,251,996 |
| Paradigm Biocapital Advisors LP | 3,840,778 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Spyre Therapeutics (SYRE)?
- UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120
- UBS Initiates Spyre Therapeutics at Buy With $120 Price Target
- Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock Offering
- Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential
What Investors Ask About Spyre Therapeutics (SYRE) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is distinctive about Spyre’s paired-antibody strategy for bowel disease?
Spyre is developing regimens that combine its integrin-directed antibody with antibodies aimed at either a tumor necrosis factor-like ligand or an interleukin pathway. This places the proposed benefit on coordinated mechanisms within the same disease portfolio, alongside the standalone candidates.
Does Spyre’s isolated reported revenue make it a commercial-stage drug company?
The isolated quarterly revenue entry does not establish recurring product sales. The annual record shows no recent revenue, while the business description identifies a development portfolio rather than marketed therapies.
Can Spyre fund its inflammatory bowel disease programs from current liquidity?
Existing cash and short-term investments provide substantial runway at the stated annualized burn rate, with no reported debt. That cushion remains sensitive to the recent acceleration in operating cash use and to further expansion of research spending.
Why can Spyre’s reported loss improve while operating cash use worsens?
Accounting results and operating cash movement capture different effects, and Spyre’s latest period shows them moving in opposite directions. The narrower net loss therefore should not be treated as evidence that the development program is consuming less cash.
What is the SYRE stock price today?
The last price recorded on this page for Spyre Therapeutics, Inc. (SYRE) is $92.91, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SYRE price target?
The analyst consensus price target for Spyre Therapeutics, Inc. (SYRE) is $119.89 (range $107.00 to $130.00, median $120.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (69 figures)
The 69 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | 221 Crescent Street, Building 23, Suite 105, Waltham, MA, 02453 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "Building 23, Waltham, MA, 02453, US". |
FMP — 59 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $92.91 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T21:14:28.127Z. | |
px.change | Change on the day | +2.86% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalization | $8.53B | FMP | Financial Modeling Prep (FMP) quote — Provider market cap uses the share class it prices; a company with more than one class may show a larger total elsewhere. Market cap record date: 2026-10-26. Source capture time was not supplied. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | +$2.58 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q4 FY2025 | $90M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $21.14–$110.18 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 637.2K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 3.11 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Cameron Turtle | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 125 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $18.74M, net result −$65.80M; FY2022 revenue $2.33M, net result −$83.81M; FY2023 revenue $890,000, net result −$338.79M; FY2024 revenue $0.00, net result −$208.02M; FY2025 revenue $0.00, net result −$155.20M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $65.50M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $16.14M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$41.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $60.41M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $15.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$45.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $90.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $44.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $12.53M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$57.17M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $45.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $11.64M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$56.89M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | −$0.3600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | −$0.7589 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_actual | EPS · reported — report date 2026-05-05 | −$0.7400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-05.eps_estimated | EPS · estimate — report date 2026-05-05 | −$0.6600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.revenue_actual | Revenue · reported — report date 2026-02-19 | $90.49M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.eps_actual | EPS · reported — report date 2026-02-19 | −$0.7000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-19.eps_estimated | EPS · estimate — report date 2026-02-19 | −$0.6600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $2.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | −$0.1500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | −$0.7608 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 1 quarters through Q4 FY2025 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $1.15B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$69.88M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 7.11× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$69.88M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$57.37M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$44.58M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$37.12M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $107.00 – $130.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $119.89 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $120.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 100 transactions · 0 purchases, 64 sales, 36 other transactions · 10 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 276 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 201 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 13,026,187 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Blackrock, INC. — shares in provider snapshot | 6,506,605 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Perceptive Advisors LLC — shares in provider snapshot | 4,319,496 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Rtw Investments, LP — shares in provider snapshot | 4,251,996 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Paradigm Biocapital Advisors LP — shares in provider snapshot | 3,840,778 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 5 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-20 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 68.82 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-24 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -24.3% · ROA -15.3% · current ratio 18.53 · earnings yield -2.3% · free-cash-flow yield -2.5% | — | UNRECORDED | Stored key metrics — Date unknown |
earn.est_eps | EPS estimate, FY2026 | $-2.72 | UNRECORDED | Stored analyst estimates — Captured 2026-10-23 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $88,600 | UNRECORDED | Stored analyst estimates — Captured 2026-10-23 · Expired observation |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 7.45× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $1.15B at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-26. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.3600) with the recorded estimate (−$0.7589) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 26 of 100 · Weak · pillars 24 / 77 / 44 / 39 / 91 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 26 (stored snapshot Oct 24, 2026) → 26 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-05.eps_actual,earn.history.depth.2026-05-05.eps_estimated,earn.history.depth.2026-02-19.revenue_actual,earn.history.depth.2026-02-19.eps_actual,earn.history.depth.2026-02-19.eps_estimated,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Spyre Therapeutics, Inc. | 2026-02-19 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-19 |
| Business description | Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $0; Liquidity basis: cash and short-term investments; Total liabilities: $71.86M; Cash and short-term investments: $1.15B; Cash and investments: $1.15B; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash runway cross-check (ours) | Years: 6.3; Method: cash and short-term investments of $1145.3M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($181.6M per year); Reaches: 2032-10; Cash basis: cash and short-term investments; Cash: $1.15B; Annualized cash use: $181.60M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $1.15B; Cash and short-term investments: $1.15B; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $1.15B; Total debt: $0; Cash and investments: $1.15B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-03; EPS estimate: -$0.8 per share The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-09-08 | OFFICIAL | SEC EDGAR filer submissions |
| Trailing twelve-month ratio set | Quick ratio: 18.53; Current ratio: 18.53; Net margin: -197.7%; Operating margin: -222.5%; Return on assets: -15.3%; Return on equity: -24.3% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
Data provided for informational purposes only.